Findings from Published Abstracts Showcase the Importance of Nicotinamide Adenine Dinucleotide (NAD+) in Glaucoma Patients and that Supplementation with Nicotinamide Riboside (NR) Demonstrate Promising Effects
July 18 2023 - 8:32AM
Business Wire
Abstracts recently published in the Association
for Research in Vision and Ophthalmology (ARVO) journal showcase
NR, one of the most efficient and well-researched NAD+ precursors,
prevented the worsening of visual field sensitivity in glaucoma
patients, and builds on research demonstrating decreased cellular
NAD+ levels and impaired mitochondrial function are associated with
Primary open-angle glaucoma (POAG)
ChromaDex Corp. (NASDAQ:CDXC), the global authority on
nicotinamide adenine dinucleotide (NAD+), announced promising
findings from two independent clinical study abstracts originally
presented this past April at the Association for Research in Vision
and Ophthalmology (ARVO) annual meeting and recently published in
the peer-reviewed ARVO journal, Investigative Ophthalmology &
Visual Science, by a team of scientists led by Dr. Christopher
Leung from the Department of Ophthalmology at the School of
Clinical Medicine, HKUMed, Hong Kong, and Dr. David F Garway-Heath,
Professor of Ophthalmology at the UCL Institute of Ophthalmology
and Moorfields Eye Hospital, London. Together, the promising
results from these abstracts suggest that glaucoma patients have
lower cellular NAD+ levels and thus replenishing NAD+ levels with a
precursor, such as nicotinamide riboside (NR), may be a potential
therapeutic strategy.
Dr. Garway-Heath’s abstract titled “Primary open angle glaucoma
patients have lower systemic mitochondrial function, associated
with lower systemic nicotinamide adenine dinucleotide (NAD) levels,
compared to Controls” observed significantly lower cellular NAD+
levels and impaired mitochondrial function in patients with primary
open-angle glaucoma (POAG). Further, higher NAD+ levels were
strongly associated with higher mitochondrial function parameters,
suggesting increased NAD+ levels are associated with improved
energy production and cellular activity. POAG is a condition where
pressure builds inside the eye, causing damage to the optic nerve
and gradual vision loss. Unlike other types of glaucoma, most
noticeable symptoms occur within advanced stages.
This research is consistent with research from a study led by
Dr. Christopher Leung, which includes preliminary data from a
clinical study set to complete in 2024, titled “Nicotinamide
Riboside for Progressing Glaucoma: A Double-blind, Parallel Group,
Randomized, Placebo-controlled Trial – A Report on
Neuroenhancement”. The data demonstrates that NR, one of the most
promising and efficient NAD+ precursors in the healthy aging space,
had beneficial effects in patients with progressing glaucoma by
preventing visual field sensitivity decline. Visual field
sensitivity is a measurement of peripheral vision and encompasses
the ability of the eye to detect and perceive visual stimuli in
different parts of the visual field. Testing for visual field
sensitivity is crucial for diagnosing the progression of
glaucoma.
Both abstracts are in line with previous preclinical studies
demonstrating that NR supplementation had protective effects in
retinal degeneration models (Zhang et al., 2020; Zhang et al.,
2021).
“This newly published preliminary research signifies a milestone
for the potential NAD+ boosting effects may have on eye health,”
said Dr. Andrew Shao, ChromaDex Senior Vice President of Global
Scientific & Regulatory Affairs. “The data builds on previously
published preclinical mouse studies indicating that retinal
degeneration exhibited depleted levels of NAD+ and supplementation
with NR had protective effects. As NR is one of the most efficient
NAD+ precursors, this may be a promising therapy for glaucoma
patients and we look forward to seeing the full peer-reviewed
published studies along with future research in this area.”
The data showcases mitochondrial function in glaucoma patients
may be improved by elevating NAD+ levels using NR as a potential
therapeutic strategy. Although more research must be conducted to
fully understand the potential benefit of NR and eye health, these
preclinical and clinical studies have established the foundation
for future research in this area.
For additional information on ChromaDex, visit
www.chromadex.com.
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to
healthy aging. The ChromaDex team, which includes world-renowned
scientists, is pioneering research on nicotinamide adenine
dinucleotide (NAD+), levels of which decline with age. ChromaDex is
the innovator behind NAD+ precursor nicotinamide riboside (NR),
commercialized as the flagship ingredient Niagen®. Nicotinamide
riboside and other NAD+ precursors are protected by ChromaDex’s
patent portfolio. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended, including statements related to whether this data
showcases mitochondrial function in glaucoma patients may be
improved by elevating NAD levels using NR as a potential
therapeutic strategy. Statements that are not a description of
historical facts constitute forward-looking statements and may
often, but not always, be identified by the use of such words as
"expects," "anticipates," "intends," "estimates," "plans,"
"potential," "possible," "probable," "believes," "seeks," "may,"
"will," "should," "could" or the negative of such terms or other
similar expressions. Risks that contribute to the uncertain nature
of these forward-looking statements include the impact of the
COVID-19 pandemic on our business and the global economy; our
history of operating losses and need to obtain additional
financing; the growth and profitability of our product sales; our
ability to maintain sales, marketing and distribution capabilities;
changing consumer perceptions of our products; our reliance on a
single or limited number of third-party suppliers; and the risks
and uncertainties associated with our business and financial
condition. More detailed information about ChromaDex and the risk
factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended December 31, 2022, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and actual results may differ materially from those
suggested by these forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230718596947/en/
ChromaDex Media Contact: Kendall Knysch, Director of
Media Relations 310-388-6706 ext. 689
kendall.knysch@chromadex.com
ChromaDex Investor Relations Contact: +1 (949) 356-1620
InvestorRelations@ChromaDex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Apr 2024 to May 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From May 2023 to May 2024